Literature DB >> 16088890

Prefabrication of vascularized bone graft using a combination of fibroblast growth factor-2 and vascular bundle implantation into a novel interconnected porous calcium hydroxyapatite ceramic.

Tomoyuki Nakasa1, Osamu Ishida, Toru Sunagawa, Atsuo Nakamae, Yuji Yasunaga, Muhammad Agung, Mitsuo Ochi.   

Abstract

The aim of this study was to create a prefabricated vascularized bone graft using a novel interconnected porous calcium hydroxyapatite ceramic (IP-CHA) by combining vascular bundle implantation and basic fibroblast growth factor (FGF)-2 administration in a rabbit model. Twenty-four Japanese white rabbits were used. The saphenous artery and vein were passed through the hole of the IP-CHA. In an experimental group, 100 microg of FGF-2 was administered into the IP-CHA before implanting the vascular bundle. In the control group, the saline was administered into the IP-CHA before implanting the vascular bundle. Finally, the IP-CHA was placed subcutaneously in the medial thigh. Neovascularization from the vascular bundle was evaluated at 2 weeks after surgery, and osteogenesis was evaluated at 4 weeks. At 2 weeks, the length and density of newly formed vessels were significantly greater in the experimental group than in the control group. Histological evaluation showed osteoid deposition in the pores of the IP-CHA at 4 weeks in the experimental group, whereas no evidence of osteoid deposition was noted in the control group. This study showed the potential of creating a vascularized bone graft of a predetermined size and shape using a combination of FGF-2 and vascular bundle implantation in the IP-CHA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16088890     DOI: 10.1002/jbm.a.30435

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  8 in total

Review 1.  * Roughness and Hydrophilicity as Osteogenic Biomimetic Surface Properties.

Authors:  Barbara D Boyan; Ethan M Lotz; Zvi Schwartz
Journal:  Tissue Eng Part A       Date:  2017-11-04       Impact factor: 3.845

Review 2.  Tissue Engineering of the Microvasculature.

Authors:  Joe Tien
Journal:  Compr Physiol       Date:  2019-06-12       Impact factor: 9.090

3.  Augmentation of surgical angiogenesis in vascularized bone allotransplants with host-derived a/v bundle implantation, fibroblast growth factor-2, and vascular endothelial growth factor administration.

Authors:  Mikko Larsen; Wouter F Willems; Michael Pelzer; Patricia F Friedrich; Michael J Yaszemski; Allen T Bishop
Journal:  J Orthop Res       Date:  2010-08       Impact factor: 3.494

Review 4.  Interconnected porous hydroxyapatite ceramics for bone tissue engineering.

Authors:  Hideki Yoshikawa; Noriyuki Tamai; Tsuyoshi Murase; Akira Myoui
Journal:  J R Soc Interface       Date:  2008-12-23       Impact factor: 4.118

5.  FGF2-adsorbed macroporous hydroxyapatite bone granules stimulate in vitro osteoblastic gene expression and differentiation.

Authors:  Ishik Jeong; Hye-Sun Yu; Mi-Kyung Kim; Jun-Hyeog Jang; Hae-Won Kim
Journal:  J Mater Sci Mater Med       Date:  2010-04       Impact factor: 3.896

6.  Novel Hybrid Hydroxyapatite Spacers Ensure Sufficient Bone Bonding in Cervical Laminoplasty.

Authors:  Nobuhiro Tanaka; Kazuyoshi Nakanishi; Naosuke Kamei; Toshio Nakamae; Shinji Kotaka; Yoshinori Fujimoto; Mitsuo Ochi; Nobuo Adachi
Journal:  Asian Spine J       Date:  2018-10-16

7.  Formation of osteon-like structures in unidirectional porous hydroxyapatite substitute.

Authors:  Takeshi Makihara; Masataka Sakane; Hiroshi Noguchi; Toshinori Tsukanishi; Yasushi Suetsugu; Masashi Yamazaki
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2018-02-13       Impact factor: 3.368

8.  Autologous platelet-rich plasma induces bone formation of tissue-engineered bone with bone marrow mesenchymal stem cells on beta-tricalcium phosphate ceramics.

Authors:  Tengbo Yu; Huazheng Pan; Yanling Hu; Hao Tao; Kai Wang; Chengdong Zhang
Journal:  J Orthop Surg Res       Date:  2017-11-21       Impact factor: 2.359

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.